Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc (HRMY) is a commercial-stage biopharmaceutical company focused on treatments for rare central nervous system sleep disorders, principally narcolepsy. Its lead product, WAKIX (pitolisant), is approved in the US for excessive daytime sleepiness and cataplexy in adults with narcolepsy and is the primary revenue driver. Investors should note the company’s growth depends on product uptake, label expansions, and successful commercial execution, while research and development and regulatory outcomes can materially affect prospects. With a market capitalisation near $1.5 billion, Harmony sits in the small-to-mid cap range where volatility can be higher than larger drugmakers. The company currently does not pay a dividend and invests earnings into marketing and development. Potential upside stems from increased market penetration, international launches and pipeline progress; downsides include competition, pricing pressures, reimbursement challenges and clinical or regulatory setbacks. This summary is for educational purposes only and not personalised investment advice.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Harmony Biosciences stock, expecting its price will rise significantly.
Financial Health
Harmony Biosciences is performing well with strong profits and cash flow, supported by good revenue.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring HRMY
Rest & Recharge
Tap into the booming wellness economy with companies revolutionizing how we sleep and relax. These carefully selected stocks represent innovative leaders in sleep technology, relaxation services, and wellness solutions that are responding to our growing desire for better rest and recovery.
Published: June 17, 2025
Explore BasketRest & Recovery
This carefully curated collection features companies at the forefront of sleep science and recovery technology. These stocks represent a growing market where innovation meets wellness, selected by professional analysts tracking the expanding health optimization trend.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Lead Product Focus
WAKIX is the company’s primary revenue engine and regulatory successes or label expansions could be meaningful, though performance can vary and competition exists.
Commercial Growth Angle
Sales growth depends on clinician adoption, patient awareness and reimbursement; these commercial levers offer upside but also bring execution risk.
Expansion Opportunities
International launches and pipeline progress could diversify revenue streams, but regulatory and market access hurdles may limit near-term impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
